NAL ER IPF Respiratory Function and Safety Study
Abroad (travel likely)RecruitingPHASE1
Conditions
Idiopathic Pulmonary Fibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic, Rochester, Minnesota, United States
Medicines Evaluation Unit Ltd., Manchester, United Kingdom
Study leads
Chief Development Officer
Study Director
Trevi Therapeutics